LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Search

Lexicon Pharmaceuticals Inc

Closed

Sector Healthcare

1.6

Overview

Share price change

24h

Current

Min

1.6

Max

1.61

Key metrics

By Trading Economics

Income

-51M

Sales

540K

702K

EPS

-0.2

Profit margin

-31,188.272

Employees

285

EBITDA

-49M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+417.39 upside

Market Stats

By TradingEconomics

Market Cap

-1.2M

510M

Previous open

1.6

Previous close

1.6

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Lexicon Pharmaceuticals Inc Chart

Related News

11 Mar 2024, 12:57 UTC

Major Market Movers

Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

417.39% upside

12 Months Forecast

Average 8.33 USD  417.39%

High 10 USD

Low 5 USD

Based on 4 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

1.61 / 1.67Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.